Puma Biotechnology | PBYI - Current Liabilities


Puma Biotechnology reported $82.73M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Daiichi Sankyo JPY 882.78B 117.08B Sep/2026
Exelixis USD 411.88M 49.95M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
Glaxosmithkline GBP 20.72B 1.71B Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Moderna USD 2.03B 506M Sep/2026
Novartis USD 32.52B 777M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Takeda JPY 2.6T 161B Sep/2026
TG Therapeutics USD 268.49M 81.38M Jun/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026